Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 4/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.90 |
| ▸ | LMNA | P02545 | 1/20 | 0.90 |
| ▸ | BLM | P54132 | 1/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.90 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Way-100,635 SCHEMBL29451114 | 1.00 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL30720034 | 1.00 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL13398069 | 1.00 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL6064589 | 0.99 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL2877337 | 0.99 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL194436 | 0.99 | HTR1A (0.98) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL29486911 | 0.99 | HTR1A (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL4077975 | 0.95 | SMN1; SMN2 (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL30366505 | 0.95 | SMN1; SMN2 (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D | |
| Way-100,635 SCHEMBL4077972 | 0.95 | SMN1; SMN2 (1.00) | HTR1AADRA1ADRD4ADRA1BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025049588-A1 | NOVEL TREATMENTS FOR OPTIC NEUROPATHIES AND GLAUCOMA | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-03-06 | — | — | WO | claimed |
| US-20240374541-A1 | ENGAGING THE CERVICAL SPINAL CORD CIRCUITRY TO RE-ENABLE VOLITIONAL CONTROL OF HAND FUNCTION IN TETRAPLEGIC SUBJECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-14 | — | — | US | claimed |
| US-20240299353-A1 | COMPOSITIONS AND METHODS FOR TREATING ADDICTIONS COMPRISING 5-MEO-DMT | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2024-09-12 | — | — | US | claimed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| EP-4304582-A1 | COMPOSITIONS AND METHODS FOR TREATING ADDICTIONS COMPRISING 5-MEO-DMT | Alvarius Pharmaceuticals Ltd. (IE) | 2024-01-17 | — | — | EP | claimed |
| EP-4299106-A2 | ACCESSING SPINAL NETWORK TO ENABLE RESPIRATORY FUNCTION | The Regents of The University of California (US) | 2024-01-03 | — | — | EP | claimed |
| WO-1999029323-A1 | USE OF 5HT1A RECEPTOR ANTAGONISTS FOR PREVENTING AND/OR TREATING TEMPORAL LOBE EPILEPSY | PRINCETON UNIVERSITY (US) | 1999-06-17 | — | — | WO | claimed |
| EP-0906100-A1 | USE OF 5-HT 1A? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1999-04-07 | — | — | EP | claimed |
| EP-0877612-A1 | USE OF PIPERAZINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS | JOHN WYETH & BROTHER LIMITED (GB) | 1998-11-18 | — | — | EP | claimed |
| WO-1997031637-A1 | USE OF 5-HT1A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-09-04 | — | — | WO | claimed |
| WO-1996001656-A1 | 5-HT1A LIGANDS | JOHN WYETH & BROTHER LIMITED (GB) | 1996-01-25 | — | — | WO | claimed |
| EP-0686047-A1 | 5-HT 1A? LIGANDS | JOHN WYETH & BROTHER LIMITED (GB) | 1995-12-13 | — | — | EP | claimed |
| EP-0512755-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| WO-1994019026-A1 | 5-HT1A LIGANDS | JOHN WYETH & BROTHER LIMITED (GB) | 1994-09-01 | — | — | WO | claimed |
| WO-1994009780-A1 | USE OF PIPERAZINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS | JOHN WYETH & BROTHER LIMITED (GB) | 1994-05-11 | — | — | WO | claimed |
| EP-0512755-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1992-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885ADRA1A 95/4885DRD4 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.